ML in biology has been portrayed as a departure from tradition, but molecular biology emerged from a similar class of formal approaches. Framed differently, ML is helping us regain the formalism we lost during molecular biology's Golden Era:.

our prior target discovery systems relied primarily on the heuristics of individual academic labs & narrow lenses upon human biology (e.g. human genetics). these were necessary because the space of ideas was larger than the space we could explore. AI in the world of bits &.

how can we realize this?. break the conception of a target as a single gene. aging & disease involve complex biologies. for our medicines to match the complexity of ailments, we need to build systems of discovery to reveal target biologies at a larger scale.

why can’t we find more targets?. good ideas get harder to find over time (h/t @I_Am_NickBloom) as the low-hanging fruit is harvested. a review of biotech history shows the clearest targets have been exploited (infectious disease, hormones). to counteract this trend, we need to.

why don’t our medicines work?. mostly, we don’t know what biology to target. we don’t know which cells or molecules to manipulate to make a patient healthy. the clearest sign of this is crowding around known targets. smart teams continually decide that new targets are so sparse,

why is this happening?. modulo Baumol’s cost disease, the main reason is that most drugs we test and develop don’t work. most drugs fail in phase 2 due to a lack of effectiveness, not safety. we’re limited by our ability to make medicines that actually preserve & restore health

the cost of discovering new medicines has been increasing dramatically over time (inflation adjusted). @JackScannell13 famously coined this phenomenon “Eroom’s Law,” the inverse of Moore’s law that we enjoy in computing.

why don’t we have more medicines?. inventing medicines has grown less efficient, limited by our knowledge of biological targets. for the 1st time, AI & genomics have the potential to make this knowledge abundant – one of the largest potential impacts of the intelligence age.

~zero-shot Ab design is the next grand challenge in structural biology. these results are a leap forward & unlock previously intractable applications. congratulations to @chaidiscovery on the achievement. sentiment & technical reality have never been farther apart in biotech.

it's always a good day when we expand the @newlimit fleet

research associate role: scientist role:

we're expanding our functional genomics team @newlimit. we're recruiting both research associates & scientists. this team runs the world's largest reprogramming screens, first humanized in vivo screens, and pushes the frontier of genomics tech each month. we grow deliberately, so.

we're also excited to welcome @RonHause as our Head of Computational Sciences. Ron previously led AI @ Shape Tx and Predictive Modeling @ Juno, Celgene, & BMS where he contributed to the origins of cell therapy. we’re excited for Ron to help us move from discovery to development.

this summer @newlimit, we built our first prototype medicine that restores multiple youthful functions in old hepatocytes. rejuvenating old cells across multiple dimensions seems more possible today than just months ago. recent highlights. - +3 TF sets that restore function in

HIV can now be reliably prevented with a simple shot every 6 months. biotech slayed a plague that just 30 years ago posed a death sentence. we should not accept the loss of our health quietly, knowing that these better worlds are possible.

Atul was an inspiration to a generation of scientists at the intersection of computer science & biomedicine. the lessons he conferred will live on for many years to come.

we generated the most visually striking data of my career @newlimit this week. we have a real opportunity to create medicines that add healthy years for everyone. come join us if you’re excited to pull that future into the present.

RT @ashleevance: Our podcast with @jacobkimmel on New Limit's efforts to try and reverse aging in our organs

RT @BiotechTVHQ: 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: @newlimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to impr….